11 ± 8 years, and 6 patients were men. Results of OH testing obtained during all inpatient or outpatient visits between June 2016 and June 2018, after 3 minutes of standing, are shown in the Figure, which graphically illustrates the diagnosis performances of the different tests. Sensitivity, calculated individually and averaged, was 93% for the ΔHR/ΔSBP ratio and 84% for the 17bpm ΔHR. It was 77% for the usual 15bpm ΔHR threshold.
International Women in MS
We thank Moneim and colleagues for calling attention to the issue of gender inequality in MS clinical trial steering committees and in authorship on publications emerging from phase 3 clinical trials. 1 Gender inequality is a long-standing problem in publication practices in general, 2 as well as in neurology, 3, 4 academic medicine, 5 and science, 6 so it is not surprising to see it reflected in the field of multiple sclerosis (MS Gender discrimination is costly, not only from a personal career perspective, but because it excludes or delays important contributions from skilled, talented individuals. This can affect progress toward a better understanding of the pathogenesis and treatment of neurological diseases, including MS.
Although it is disheartening to see continuing evidence of the gender discrimination that permeates not only academic medicine and science, but also society at large, we are encouraged that there is interest in shedding greater light on the issue. We believe that it is time for the MS community to work harder toward achieving equal participation by all women at all levels. To this end, we submit this letter as a call to action, and offer the following recommendations:
1. Develop structured opportunities to foster greater awareness of gender-based imbalances and existing biases, including implicit or unconscious bias. This can occur on a committee level in professional organizations and should include representatives from pharmaceutical companies. The primary goal would be to establish task forces charged with gathering and analyzing data on gender concerning: a. Clinical trial leadership, including clinical trial steering committees, data safety monitoring boards, authorship committees, and other active committees. b. Participation by physicians and basic scientists on editorial boards and grant review panels and in scientific programs, professional organizations, and academic institutions, including neurology departments, as well as in other relevant entities. 2. Establish specific goals toward achieving equal representation by women at all levels in a timely fashion. There are many models and transformative voices 3, 6, [10] [11] [12] that can be tapped in efforts to swing the pendulum toward a truly equal opportunity environment in the MS community. It is clear that conscious, thoughtful, and persistent efforts by all stakeholders, both men and women, are needed to implement enduring change worthy of celebration. We look forward to participating in an ongoing and collaborative dialogue toward achieving this important goal. This letter was authored by Emmanuelle Waubant,
